EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discontinuation of neoadjuvant therapy does not influence postoperative short-term outcomes in elderly patients (≥ 70 years) with resectable gastric cancer: a population-based study from the dutch upper gastrointestinal cancer audit (DUCA) data

Jingpu Wang, Zhouqiao Wu, Eline M de Groot, Alexandre Challine, Nadia Haj Mohammad, Stella Mook, Lucas Goense, Jelle P Ruurda, Richard van Hillegersberg

Gastric Cancer · 2024

DOI: 10.1007/s10120-024-01522-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gastric Cancer, 2024. Verfasst von Jingpu Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University Medical Center Utrecht, Utrecht University, PO Box 85500, Utrecht, 3508 GA, The Netherlands. Hauptthemen laut MEDLINE: Stomach Neoplasms, Neoadjuvant Therapy, Gastrectomy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Scholarship Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

For the elderly patients with gastric cancer, it may be more challenging to tolerate complete neoadjuvant therapy (NAT). The impact of discontinued NAT on the surgical safety and pathological outcomes of elderly patients with poor tolerance remains poorly understood.

Methods

Gastric cancer patients received gastrectomy with curative intent from the Dutch upper GI cancer audit (DUCA) database were included in this study. The independent association of age with not initiating and discontinuation of NAT was assessed with restricted cubic splines (RCS). According to the RCS results, age ≥ 70 years was defined as elderly. Short-term postoperative outcomes and pathological results were compared between elderly patients who completed and discontinued NAT.

Results

Between 2011- 2021, total of 3049 patients were included. The risk of not initiating NAT increased from 70 years. In 1954 (64%) patients receiving NAT, the risk of discontinuation increased from 55 years, reaching the peak around 74 years. In the elderly, discontinued NAT was not independently associated with worse 30-day mortality, overall complications, anastomotic leakage, re-intervention, and pathologic complete response, but was associated with a higher risk of R1/2 resection ( p -value = 0.001), higher ypT stage ( p -value = 0.004), ypN + ( p -value = 0.008), and non-response ( p-value = 0.012).

Conclusion

A decreased utilization of NAT has been observed in Dutch gastric cancer patients from 70 years due to old age considerations, possibly because of their high risk of discontinuation. Increasing the utilization of NAT may not adversely impact the surgical safety of gastric cancer population ≥ 70 years and may contribute to better pathological results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsNeoadjuvant TherapyGastrectomyHumansAgedMaleFemaleNetherlandsMiddle AgedAged, 80 and overPostoperative ComplicationsTreatment OutcomeWithholding Treatment

Stichwörter der Autor:innen

Elderly patientsGastric cancerNeoadjuvant therapyShort-term outcomes

Autor:innen und Institutionen

  • Department of Surgery, University Medical Center Utrecht, Utrecht University, PO Box 85500, Utrecht, 3508 GA, The Netherlands.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital and Institute, Beijing, China.
  • Department of Digestive Surgery, AP-HP, Hôpital Saint Antoine, 75012, Paris, France.
  • Department of Imaging and Cancer, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Departments of Radiation Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Department of Surgery, University Medical Center Utrecht, Utrecht University, PO Box 85500, Utrecht, 3508 GA, The Netherlands. r.vanhillegersberg@umcutrecht.nl.

Förderung

  • China Scholarship Council

Zitieren

APA

Wang, J., Wu, Z., de Groot, E. M., Challine, A., Mohammad, N. H., Mook, S., Goense, L., Ruurda, J. P., & van Hillegersberg, R. (2024). Discontinuation of neoadjuvant therapy does not influence postoperative short-term outcomes in elderly patients (≥ 70 years) with resectable gastric cancer: a population-based study from the dutch upper gastrointestinal cancer audit (DUCA) data. Gastric Cancer. https://doi.org/10.1007/s10120-024-01522-5

Vancouver

Wang J, Wu Z, de Groot EM, Challine A, Mohammad NH, Mook S, et al. Discontinuation of neoadjuvant therapy does not influence postoperative short-term outcomes in elderly patients (≥ 70 years) with resectable gastric cancer: a population-based study from the dutch upper gastrointestinal cancer audit (DUCA) data. Gastric Cancer. 2024. doi:10.1007/s10120-024-01522-5

BibTeX
@article{Wang2024,
  author = {Wang, Jingpu and Wu, Zhouqiao and de Groot, Eline M and Challine, Alexandre and Mohammad, Nadia Haj and Mook, Stella and Goense, Lucas and Ruurda, Jelle P and van Hillegersberg, Richard},
  title = {Discontinuation of neoadjuvant therapy does not influence postoperative short-term outcomes in elderly patients (≥ 70 years) with resectable gastric cancer: a population-based study from the dutch upper gastrointestinal cancer audit (DUCA) data},
  journal = {Gastric Cancer},
  year = {2024},
  doi = {10.1007/s10120-024-01522-5}
}
Kostenlos starten →